Based on diclofenac component: Safety and efficacy in pregnant women have not been established. Exposure late in pregnancy may lead to premature closure of the ductus arteriosus and may inhibit uterine contractions.
Based on misoprostol component: Misoprostol is an abortifacient. Administration by any route is contraindicated in pregnancy. Reports of fetal death and congenital anomalies have been received after the use of misoprostol as an abortifacient.
Based on diclofenac component: Fatal asthmatic and anaphylactoid reactions have occurred in patients with "aspirin triad." Use with caution in patients with CHF, hypertension, dehydration, decreased renal or hepatic function, history of GI disease (bleeding, ulcers, or previous GI symptoms with NSAID use), or those receiving anticoagulants and/or corticosteroids. Use lowest effective dose for shortest period possible; bleeding risk has been correlated to dose and duration of therapy. Gastrointestinal bleeding may occur without prior symptoms of gastrointestinal irritation. Elderly are at a high risk for adverse effects from NSAIDs. As many as 60% of elderly can develop peptic ulceration and/or hemorrhage asymptomatically.
Use of NSAIDs can compromise existing renal function especially when Clcr<30 mL/minute. CNS adverse effects such as confusion, agitation, and hallucination are generally seen in overdose or high-dose situations; however, elderly may demonstrate these adverse effects at lower doses than younger adults. Withhold for at least 4-6 half-lives prior to surgical or dental procedures.
Rare cases of severe hepatic reactions (including necrosis, jaundice, fulminant hepatitis) have been reported. Vision changes (including changes in color) have been rarely reported with oral diclofenac.
Based on misoprostol component: Safety and efficacy have not been established in children <18 years of age; use with caution in patients with renal impairment and the elderly; not to be used in pregnant women or women of childbearing potential unless woman is capable of complying with effective contraceptive measures; therapy is normally begun on the second or third day of next normal menstrual period. Uterine perforation and/or rupture have been reported in association with intravaginal use to induce labor or with combined oral/intravaginal use to induce abortion. Should not be used as a cervical-ripening agent for induction of labor or termination of pregnancy.
>10%: Gastrointestinal: Abdominal pain (21%), diarrhea (19%), nausea (11%), dyspepsia (14%)
1% to 10%:
Endocrine & metabolic: Transaminases increased
Gastrointestinal: Flatulence (9%)
Hematologic: Anemia
Miscellaneous: Anaphylactic reactions
Postmarketing and/or case reports (associated with misoprostol): Uterine rupture, fetal or infant death (when used during pregnancy)
Increased effect/toxicity: Aspirin (shared toxicity), digoxin (elevated digoxin levels), warfarin (synergistic bleeding potential), cyclosporine (increased nephrotoxicity), lithium (increased lithium levels)
Decreased effects: Aspirin (displaces diclofenac from binding sites), antihypertensive agents (decreased blood pressure control), antacids (may decrease absorption)
ACE inhibitors: Antihypertensive effects may be decreased by concurrent therapy with NSAIDs; monitor blood pressure
Angiotensin II antagonists: Antihypertensive effects may be decreased by concurrent therapy with NSAIDs; monitor blood pressure
CYP1A2 substrates: Diclofenac may increase the levels/effects of CYP1A2 substrates. Example substrates include aminophylline, fluvoxamine, mexiletine, mirtazapine, ropinirole, theophylline, and trifluoperazine.
CYP3A4 substrates: Diclofenac may increase the levels/effects of CYP3A4 substrates. Example substrates include benzodiazepines, calcium channel blockers, mirtazapine, nateglinide, nefazodone, tacrolimus, and venlafaxine. Selected benzodiazepines (midazolam and triazolam), cisapride, ergot alkaloids, selected HMG-CoA reductase inhibitors (lovastatin and simvastatin), and pimozide are generally contraindicated with strong CYP3A4 inhibitors.
Methotrexate: Severe bone marrow suppression, aplastic anemia, and GI toxicity have been reported with concomitant NSAID therapy. Avoid use during moderate or high-dose methotrexate (increased and prolonged methotrexate levels). NSAID use during low-dose treatment of rheumatoid arthritis has not been fully evaluated; extreme caution is warranted.
Adults:
Arthrotec® 50:
Osteoarthritis: 1 tablet 2-3 times/day
Rheumatoid arthritis: 1 tablet 3-4 times/day
For both regimens, if not tolerated by patient, the dose may be reduced to 1 tablet twice daily
Arthrotec® 75:
Patients who cannot tolerate full daily Arthrotec® 50 regimens: 1 tablet twice daily
Note: The use of these tablets may not be as effective at preventing GI ulceration
Elderly: No specific dosage adjustment is recommended; may require reduced dosage due to lower body weight; monitor renal function
Conlin P, Moore T, Swartz S, et al, "Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients," Hypertension , 2000, 36(3):461-5.
Morgan TO, Anderson A, and Bertram D, "Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril," Am J Hypertens , 2000, 13(11):1161-7.
|
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process . A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch). |